

Supplemental Table 1. Individual KIR-ligand genotype alone is not associated with patient outcome.

Maximum tumor shrinkage				Progression-free survival				Overall survival				
n	Mean(%)	SD(%)	p-value*	n	# of Events	Median PFS (95% CI) (months)	p-value*	n	# of Events	Median OS (95% CI) (months)	p-value*	
HLA-C genotype												
HLA-C1/C1	36	7.2	73.2	37	36	4.0 (1.6-7.5)		37	26	43.1 (13.7-56.0)		
HLA-C1/C2	50	18.8	59.3	0.68	51	46	4.4 (2.5-6.2)	0.74	51	33	42.6 (27.2-73.4)	0.46
HLA-C2/C2	17	8.9	55.8		17	15	2.8 (2.3-7.0)		17	11	52.6 (16.0-INF)	
HLA-C1+	86	14.0	65.3	0.77	88	82	4.2 (2.5-5.3)	0.87	88	59	42.6 (27.2-54.1)	0.73
HLA-C1-	17	8.9	55.8		17	15	2.8 (2.3-7.0)		17	11	52.6 (16.0-INF)	
HLA-C2-	36	7.2	73.2	0.49	37	36	4.0 (1.6-7.5)	0.50	37	26	43.1 (13.7-56.0)	0.22
HLA-C2+	67	16.3	58.2		68	61	4.2 (2.5-5.3)		68	44	45.3 (36.1-61.1)	
HLA-B genotype												
HLA-Bw4+	73	14.4	60.4	0.75	74	66	3.9 (2.4-5.3)	0.43	74	47	42.8 (28.4-54.1)	0.49
HLA-Bw4-	30	10.0	71.9		31	31	4.4 (2.3-7.5)		31	23	43.1 (20.2-61.9)	
2DL1+ patients												
2DL1-ligand present	65	16.8	59.0	0.54	66	59	4.3 (2.5-5.7)	0.52	66	42	47.7 (36.1-61.1)	0.23
2DL1-ligand missing	35	8.5	73.9		36	35	4.1 (1.6-7.5)		36	25	43.1 (15.2-56.0)	
2DL2/3+ patients												
2DL2/3-ligand present	86	14.0	65.3	0.77	88	82	4.2 (2.5-5.3)	0.87	88	59	42.6 (27.2-54.1)	0.73
2DL2/3-ligand missing	17	8.9	55.8		17	15	2.8 (2.3-7.0)		17	11	52.6 (16.0-INF)	
3DL1+ patients												
3DL1-ligand present	70	14.0	60.3	0.77	71	63	3.7 (2.3-4.8)	0.48	71	45	42.8 (28.4-52.6)	0.49
3DL1-ligand missing	30	10.0	71.9		31	31	4.4 (2.3-7.5)		31	23	43.1 (20.2-61.9)	

* Linear regression models were used for maximum tumor shrinkage analyses; Log-rank tests and Cox proportional hazards regression models were used for PFS and OS analyses.